Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders
Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders
复制标题
DOI：
10.1080/08869634.2003.11746254
复制
发表时间：
2003-07-01
影响因子：
1.6
通讯作者：
Barbosa, JRD
中科院分区：
文献类型：
--
作者：
Rizzatti-Barbosa, CM;Nogueira, MTP;Barbosa, JRD
颞下颌关节紊乱病（TMD）的特征是影响颞下颌关节和/或咀嚼肌的综合症状。两种最常见的临床TMD症状是疼痛和功能障碍。疼痛通常是由功能障碍引起的，紧急治疗的重点是控制它。最近对TMD的研究已经导致推荐抗抑郁药作为持续神经痛的支持治疗。这项双盲研究的目的是验证抗抑郁药（阿米替林）作为慢性TMD疼痛治疗支持的有效性。12名女性志愿者慢性TMD疼痛分为两组，治疗14天：组1与25毫克/天的阿米替林和组2与安慰剂。在治疗前7天（基线）、14天治疗期间和治疗后7天内，每天使用视觉模拟量表（VAS）评估疼痛和不适的强度。结果显示，在基线开始的三周内，第1组（75%）与第2组（28%）相比疼痛和不适显著减少（p< 0.01）。阿米替林被证明是一种有效的替代治疗慢性疼痛的TMD患者。
Temporomandibular disorder (TMD) is characterized by a combination of symptoms affecting the temporomandibular joint and/or chewing muscles. The two most common clinical TMD symptoms are pain and dysfunction. Pain is usually Caused by dysfunction, and emergency therapy has focused on controlling it. Recent investigations into TMD have led to the recommendation of antidepressants as a supporting treatment against constant neuralgic pain. The aim of this double-blind study was to verify the efficiency of antidepressants (amitriptyline) as a support in the treatment of chronic TMD pain. Twelve female volunteers presenting chronic TMD pain were divided into two groups and treated for 14 days: Group 1 with 25 mg/day of amitriptyline and Group 2 with a placebo. The intensity of pain and discomfort was evaluated daily, using a visual analog scale (VAS), over a period of seven days preceding the treatment (baseline), during the 14-day treatment, and for seven days after the treatment. The results revealed a significant reduction of pain and discomfort in Group 1 (75%) compared to Group 2 (28%) during the three weeks beginning at baseline (p< 0.01). Amitriptyline proved to be an efficient alternative treatment for chronic pain in TMD patients.